226 related articles for article (PubMed ID: 31808886)
41. Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.
Huang LW; Olin RL
J Geriatr Oncol; 2017 Nov; 8(6):417-420. PubMed ID: 28835351
[TBL] [Abstract][Full Text] [Related]
42. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.
Porter DL; Hexner EO; Cooley S; Miller JS
Cancer Treat Res; 2009; 144():497-537. PubMed ID: 19779876
[No Abstract] [Full Text] [Related]
43. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
Derman BA; Kordas K; Molloy E; Chow S; Dale W; Jakubowiak AJ; Jasielec J; Kline JP; Kosuri S; Lee SM; Liu H; Riedell PA; Smith SM; Bishop MR; Artz AS
J Geriatr Oncol; 2021 May; 12(4):585-591. PubMed ID: 33162369
[TBL] [Abstract][Full Text] [Related]
44. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
45. Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.
Yao S; Hahn T; Zhang Y; Haven D; Senneka M; Dunford L; Parsons S; Confer D; McCarthy PL
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1459-64. PubMed ID: 23811537
[TBL] [Abstract][Full Text] [Related]
46. What the internist should know about stem cell transplant in the elderly patient.
Medinger M; Passweg J
Eur J Intern Med; 2018 Dec; 58():43-47. PubMed ID: 29960832
[TBL] [Abstract][Full Text] [Related]
47. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies.
Gratwohl A; Baldomero H; Schwendener A; Rocha V; Apperley J; Frauendorfer K; Niederwieser D; ;
Bone Marrow Transplant; 2009 Feb; 43(4):275-91. PubMed ID: 19169283
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.
Champlin R; Khouri I; Kornblau S; Marini F; Anderlini P; Ueno NT; Molldrem J; Giralt S
Hematol Oncol Clin North Am; 1999 Oct; 13(5):1041-57, vii-viii. PubMed ID: 10553260
[TBL] [Abstract][Full Text] [Related]
49. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
[TBL] [Abstract][Full Text] [Related]
50. How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT.
Jayani RV
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):709-714. PubMed ID: 38066893
[TBL] [Abstract][Full Text] [Related]
51. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Al Malki MM; Nathwani N; Yang D; Armenian S; Dadwal S; Salman J; Mokhtari S; Cao T; Sandhu K; Rouse M; Mei M; Ali H; Parker P; Alvarnas J; Smith E; Donnell MO; Marcucci G; Snyder D; Nademanee A; Forman SJ; Stein A; Nakamura R
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1828-1835. PubMed ID: 29753158
[TBL] [Abstract][Full Text] [Related]
52. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
Loh KP; Christofyllakis K; Huang LW; Mims A
J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
[No Abstract] [Full Text] [Related]
53. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.
Klepin HD; Tooze JA; Pardee TS; Ellis LR; Berenzon D; Mihalko SL; Danhauer SC; Rao AV; Wildes TM; Williamson JD; Powell BL; Kritchevsky SB
J Am Geriatr Soc; 2016 Oct; 64(10):1988-1995. PubMed ID: 27627675
[TBL] [Abstract][Full Text] [Related]
54. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
Novitzky N; Thomas V; du Toit C; McDonald A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
[TBL] [Abstract][Full Text] [Related]
55. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
56. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.
Ustun C; Courville EL; DeFor T; Dolan M; Randall N; Yohe S; Bejanyan N; Warlick E; Brunstein C; Weisdorf DJ; Linden MA
Biol Blood Marrow Transplant; 2016 Apr; 22(4):669-675. PubMed ID: 26551635
[TBL] [Abstract][Full Text] [Related]
57. [Hematopoietic stem cell transplantation for treatment of acute leukemia].
Harada M
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1387-95. PubMed ID: 10500524
[TBL] [Abstract][Full Text] [Related]
58. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
[TBL] [Abstract][Full Text] [Related]
59. [Treatment outcome of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies not in remission].
Bao HY; Wu XJ; Ma X
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):156-7. PubMed ID: 22780938
[No Abstract] [Full Text] [Related]
60. Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.
El Cheikh J; Otrock ZK; Qannus AA; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):304-10. PubMed ID: 26923326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
